Direct Oral Anticoagulants in the Setting of Catheter Ablation of Atrial Fibrillation: State of art.
Journal
Current problems in cardiology
ISSN: 1535-6280
Titre abrégé: Curr Probl Cardiol
Pays: Netherlands
ID NLM: 7701802
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
29
04
2020
accepted:
30
04
2020
pubmed:
24
6
2020
medline:
16
7
2021
entrez:
24
6
2020
Statut:
ppublish
Résumé
Atrial fibrillation (AF) represents the arrhythmia of greatest clinical impact and catheter ablation of AF (CAAF) has become the most effective strategy for rhythm control in selected patients. Therefore, appropriate anticoagulation strategies are of paramount importance for patients undergoing CAAF, especially those at high risk, such those with high CHA2DS2VASc scores. Optimal management of anticoagulation before, during, and after CAAF is crucial. Several studies have evaluated the use of different anticoagulation strategies in the periprocedural period. Randomized controlled trial seem to suggest that in patients undergoing CAAF, uninterrupted (or minimally interrupted) direct oral anticoagulants (DOACs) provides an alternative to continuous vitamin K antagonists strategy, with low thromboembolic and bleeding risk.
Identifiants
pubmed: 32571567
pii: S0146-2806(20)30099-2
doi: 10.1016/j.cpcardiol.2020.100622
pii:
doi:
Substances chimiques
Anticoagulants
0
Vitamin K
12001-79-5
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
100622Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.